Indication: Low-Grade Glioma (LGG)

A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

Sub-indication: Low-Grade Glioma (LGG)

Study Type: Drug Study

Principal Investigator: Ashok Raj, M.D.
Norton Children's Cancer Institute, affiliated with the UofL School of Medicine

Sponsor: Sponsor: Children's Oncology Group (COG)

Learn more at ClinicalTrials.gov

Email for more information: NCRI-Cancer@NortonHealthcare.org

Search our entire site.